Anhydrous Soft Glycopyrrolate Formulations for Local Sweat Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical anticholinergic agents used for treating hyperhidrosis often exhibit systemic side effects and lack stable, pharmaceutically acceptable formulations with commercially viable shelf-life.
Innovation Solution
Development of a stable, anhydrous topical composition comprising soft anticholinergic esters, such as glycopyrrolate esters, in anhydrous ethanol with optional gelling or viscosity-controlling agents, providing a formulation that minimizes systemic side effects and enhances stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If topical anticholinergic agents are administered to treat hyperhidrosis, then sweat production is reduced, but systemic side effects occur
Solution Approach 1:
The patent modifies the chemical structure of anticholinergic compounds by creating esters with specific lipophilic properties. These structural parameter changes enable the drugs to be rapidly metabolized by esterases in the skin and systemic circulation, converting them to inactive forms before they can cause significant systemic side effects, while maintaining effective local action on sweat glands
Solution Approach 2:
The soft anticholinergic esters are designed to be short-lived in the body, rapidly hydrolyzing to inactive metabolites. This transient activity profile allows effective local treatment of hyperhidrosis while minimizing the duration of systemic exposure and associated side effects, essentially creating a 'disposable' drug molecule that fulfills its therapeutic purpose and then deactivates
2Duration of action of stationary object
If stable formulations of soft anticholinergic esters are developed, then shelf-life is extended, but formulation complexity increases
Solution Approach 1:
The patent employs anhydrous conditions and inert or low-water-activity vehicles (such as alcohols, oils, or gelling agents with limited water content) to create a formulation environment that prevents hydrolysis of the ester bonds. This inert formulation approach stabilizes the soft anticholinergic esters during storage, extending shelf-life without requiring complex stabilizing systems
Solution Approach 2:
The patent adjusts formulation parameters such as pH, water activity, and presence of antioxidants or chelating agents to optimize stability. By carefully controlling these parameters, the formulation achieves extended shelf-life while maintaining relative simplicity, avoiding the need for multiple complex stabilizing components
Data Source
AI summary
Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.